Semaglutide and the Heart: What SELECT Changed for Everyone Choosing a GLP-1

For two decades, weight-loss medicine carried an asterisk: it improved numbers on a chart, but no obesity drug had ever proven it prevented heart attacks. SELECT removed the asterisk. Understanding exactly what this landmark semaglutide trial showed — and the two live debates it started — is now essential to choosing between molecules, because cardiovascular protection is the strongest card semaglutide holds against tirzepatide's bigger weight numbers.

The trial, plainly

SELECT enrolled 17,604 adults aged 45+ with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) and a BMI of 27 or higher — but, crucially, without diabetes, the population where GLP-1 cardiovascular benefit was already known. Participants received semaglutide 2.4 mg weekly or placebo on top of standard cardiac care and were followed for a mean of about 40 months. The primary endpoint was major adverse cardiovascular events (MACE): cardiovascular death, nonfatal heart attack, nonfatal stroke.

The result and its texture

Semaglutide reduced MACE by 20% — hazard ratio 0.80 — a result both statistically robust and clinically meaningful in a secondary-prevention population already on statins and antihypertensives. Event curves separated early, within months, and every MACE component trended favorably, with nonfatal myocardial infarction driving much of the benefit; heart-failure outcomes and all-cause mortality also trended in semaglutide's favor. Mean weight loss was 9.4% — notably less than STEP 1's 14.9%, as expected in an older cardiac population — and here is where the first debate lives: the early separation and analyses across baseline weights suggest the protection is not purely a weight story. Anti-inflammatory effects (CRP fell substantially), blood-pressure and lipid improvements, and possibly direct vascular GLP-1 receptor effects likely share credit. Regulators found the package convincing: in March 2024 the FDA expanded Wegovy's label to include reducing cardiovascular risk in adults with established CVD and overweight or obesity — and because that is a cardiovascular indication rather than a weight one, it opened Medicare Part D coverage for this population.

The second debate: what about tirzepatide?

Tirzepatide's dedicated cardiovascular story is younger. Its outcomes trial in type 2 diabetes, SURPASS-CVOT, compared tirzepatide against dulaglutide — an active GLP-1 with proven cardiovascular benefit — and 2025 reporting indicated tirzepatide met noninferiority with results at least as good as its comparator; but that is a different design than SELECT's placebo comparison in non-diabetic cardiac patients, and no completed trial yet answers SELECT's exact question for tirzepatide (verify current readouts — this area moves quickly). Mechanistically there is every reason for optimism: tirzepatide improves the same risk factors, often more. Evidence-based medicine, though, pays out on completed trials, not extrapolations. Today, for a patient with established cardiovascular disease, semaglutide is the molecule with a placebo-controlled MACE reduction and an FDA cardiovascular indication in that exact population; tirzepatide is the molecule with larger average weight loss and a strong but less directly applicable cardiac file.

How to actually use this in the choosing decision

If you have had a heart attack, stroke, or documented PAD: semaglutide's SELECT evidence and CV indication make it the default conversation-starter, and the indication frequently changes insurance math in your favor — including Medicare. If your priority is maximum weight reduction and your cardiac history is clean, tirzepatide's head-to-head superiority in SURMOUNT-5 (20.2% vs 13.7%) argues the other way; our full comparison walks that trade. If you sit in between — high risk factors, no established disease — you are outside SELECT's enrolled population, and honesty requires saying the trial doesn't directly answer your case; primary-prevention questions remain open. And a structural point for cash-pay shoppers: compounded semaglutide is not Wegovy, was not in SELECT, and carries no indication; the cardiovascular argument is strongest when it travels with the approved product and its coverage pathways.

Bottom line

SELECT converted obesity treatment from cosmetic-adjacent to cardiology: a 20% MACE reduction, on top of modern cardiac care, in people without diabetes. It is the reason "which molecule?" now has two defensible answers — the bigger number on the scale, or the completed trial on the heart — and the reason your cardiac history, not a leaderboard, should pick between them.

The result in absolute terms

Relative risk makes headlines; absolute risk makes decisions. In SELECT, roughly 6.5% of semaglutide patients versus 8.0% of placebo patients had a primary event over a mean 40 months — an absolute reduction of about 1.5 percentage points, which translates to a number needed to treat in the neighborhood of 65–70 for three-plus years to prevent one major event. For a secondary-prevention therapy added to statins and blood-pressure control, that's genuinely competitive with established cardiology drugs. The components behaved unevenly and informatively: nonfatal heart attack fell most (hazard ratio around 0.72), cardiovascular death trended down (around 0.85), and stroke moved least (around 0.93) — approximate figures worth re-checking against the paper before quoting. Heart-failure outcomes and a prespecified kidney composite also favored semaglutide, foreshadowing the FLOW kidney-trial result that followed.

Safety inside a 17,000-person trial

SELECT doubled as the largest placebo-controlled safety database the class has ever produced in people without diabetes. Serious adverse events were actually less frequent on semaglutide than placebo — largely because cardiovascular events count as serious adverse events. The cost showed up in tolerability: discontinuation for adverse effects ran roughly twice placebo (about 17% versus 8%), overwhelmingly gastrointestinal. Reassuringly for long-running questions, no excess signal emerged for pancreatitis, and gallbladder disease showed the expected modest increase that tracks rapid weight loss generally. For anyone weighing internet-era safety scares against data, a 40-month randomized experiment in 17,604 high-risk adults is about as good as real-world evidence gets.

Where the benefit probably comes from

Three observations argue the protection isn't only pounds. The event curves separated within the first months, before most weight had been lost. The benefit appeared across baseline BMI categories, including the merely overweight. And C-reactive protein — the workhorse inflammation marker — fell substantially, echoing GLP-1 effects on vascular inflammation seen across the class. None of this is settled mechanism; all of it matters practically, because it implies patients who lose modest weight on the drug may still bank cardiovascular benefit, and it cautions against assuming any weight-loss method — surgery, diet, a different molecule — automatically inherits SELECT's result.

Questions people actually ask

Does Ozempic at 1 mg give the same protection? SELECT used 2.4 mg in people without diabetes. Separately, semaglutide 0.5–1 mg showed cardiovascular benefit in diabetics (SUSTAIN-6), so the molecule's cardiac story spans doses — but the non-diabetic indication and its coverage pathway are built on 2.4 mg. Dose per label for the indication you're claiming.

Does compounded semaglutide carry the SELECT benefit? Biologically plausible, legally and evidentially no: compounded product is not FDA-approved for anything, was not the trial article, and cannot be marketed with the cardiovascular claim. If the heart indication is your reason, the approved product — and the insurance doors it opens, including Medicare — is the coherent choice.

I have heart disease and I'm already thriving on tirzepatide — switch? Not by internet verdict. Tirzepatide improves the same risk factors, its diabetes outcomes trial performed at least as well as an active cardioprotective comparator, and switching a working therapy has its own costs. This is a cardiologist conversation where SELECT is exhibit A, not a self-service swap.

Will insurance actually cover it for my heart? Often more readily than for weight: the March 2024 indication moved Wegovy into "treats established disease" territory, which Medicare Part D can cover and many commercial plans process under different criteria than obesity requests. Bring the diagnosis codes for your cardiovascular history; policies vary and shift, so verify yours this month, not last year's summary.

Who SELECT did not enroll — and why that matters to you

Trials answer questions for the people inside them. SELECT excluded diabetes by design (that evidence already existed), enrolled a population that skewed male (women were roughly a quarter of participants) and largely on strong background cardiac therapy, and required established disease — a prior event or documented peripheral arterial disease — rather than risk factors alone. If you're a 52-year-old with hypertension, high LDL, and a worrying family history but no event on record, you are the primary-prevention patient the trial deliberately didn't study; your case runs on extrapolation plus risk-factor logic, which is respectable but different, and worth naming honestly in the exam room. Conversely, if you're squarely inside the enrolled profile, you're standing on some of the firmest ground in all of obesity medicine — a place this field had never stood before 2023.

References

Primary sources for this article (verify against PubMed / FDA before external citation): Lincoff et al., SELECT, NEJM 2023; FDA Wegovy label expansion (March 2024); CMS guidance on Part D coverage for the CV indication (2024); SURPASS-CVOT reporting (2025 — verify current publication); Wilding et al., STEP 1 NEJM 2021; Aronne et al., SURMOUNT-5 NEJM 2025.